- Author:
Eun Jeong KOH
1
;
Han Na KIM
;
Tian Ze MA
;
Ha Young CHOI
;
Yong Geun KWAK
Author Information
- Publication Type:Original Article
- Keywords: Moyamoya disease; Proteome
- MeSH: Apolipoprotein C-III; Biomarkers; Complement C1 Inhibitor Protein; Electrophoresis; Humans; Mass Spectrometry; Moyamoya Disease; Proteins; Proteome; Sample Size
- From:Journal of Korean Neurosurgical Society 2010;48(1):8-13
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: The etiology and pathogenesis of moyamoya disease remain unclear. Furthermore, the definitive diagnostic protein-biomarkers for moyamoya disease are still unknown. The present study analyzed serum proteomes from normal controls and moyamoya patients to identify novel serological biomarkers for diagnosing moyamoya disease. METHODS: We compared the two-dimensional electrophoresis patterns of sera from moyamoya disease patients and normal controls and identified the differentially-expressed spots by matrix-assisted laser desorption/ionization-time-of flight mass spectrometry and electrospray ionization quadruple time-of-flight mass spectrometry. RESULTS: We found and analyzed 22 differently-expressed proteomes. Two proteins were up-regulated. Twenty proteins were down-regulated. Complement C1 inhibitor protein and apolipoprotein C-III showed predominantly changed expressions (complement C1 inhibitor protein averaged a 7.23-fold expression in moyamoya patients as compared to controls, while apolipoprotein C-III averaged a 0.066-fold expression). CONCLUSION: Although our study had a small sample size, our proteomic data provide serologic clue proteins for understanding moyamoya disease.